SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5 | -100.0% | 212 | -77.7% | 0.00% | – |
| Q1 2022 | $16,000 | -69.8% | 951 | -60.9% | 0.00% | – |
| Q4 2021 | $53,000 | +76.7% | 2,435 | +80.1% | 0.00% | – |
| Q4 2020 | $30,000 | -95.7% | 1,352 | -97.1% | 0.00% | -100.0% |
| Q2 2020 | $691,000 | +215.5% | 46,663 | +132.8% | 0.00% | – |
| Q1 2020 | $219,000 | -38.8% | 20,046 | -50.9% | 0.00% | -100.0% |
| Q4 2019 | $358,000 | +411.4% | 40,826 | +441.2% | 0.00% | – |
| Q2 2019 | $70,000 | +288.9% | 7,544 | +119.9% | 0.00% | – |
| Q1 2019 | $18,000 | +200.0% | 3,430 | +122.2% | 0.00% | – |
| Q4 2018 | $6,000 | -95.9% | 1,544 | -91.6% | 0.00% | – |
| Q3 2018 | $148,000 | +4833.3% | 18,438 | +3609.9% | 0.00% | – |
| Q2 2018 | $3,000 | – | 497 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |